Literature DB >> 26780512

PTEN recruitment controls synaptic and cognitive function in Alzheimer's models.

Shira Knafo1,2,3, Cristina Sánchez-Puelles1, Ernest Palomer1, Igotz Delgado2, Jonathan E Draffin1, Janire Mingo4, Tina Wahle5,6, Kanwardeep Kaleka7, Liping Mou8, Inmaculada Pereda-Perez9, Edvin Klosi10, Erik B Faber10, Heidi M Chapman10, Laura Lozano-Montes1, Ana Ortega-Molina11, Lara Ordóñez-Gutiérrez1,12, Francisco Wandosell1,12, Jose Viña13, Carlos G Dotti1, Randy A Hall8, Rafael Pulido3,4, Nashaat Z Gerges7, Andrew M Chan14, Mark R Spaller10, Manuel Serrano11, César Venero9, José A Esteban1.   

Abstract

Dyshomeostasis of amyloid-β peptide (Aβ) is responsible for synaptic malfunctions leading to cognitive deficits ranging from mild impairment to full-blown dementia in Alzheimer's disease. Aβ appears to skew synaptic plasticity events toward depression. We found that inhibition of PTEN, a lipid phosphatase that is essential to long-term depression, rescued normal synaptic function and cognition in cellular and animal models of Alzheimer's disease. Conversely, transgenic mice that overexpressed PTEN displayed synaptic depression that mimicked and occluded Aβ-induced depression. Mechanistically, Aβ triggers a PDZ-dependent recruitment of PTEN into the postsynaptic compartment. Using a PTEN knock-in mouse lacking the PDZ motif, and a cell-permeable interfering peptide, we found that this mechanism is crucial for Aβ-induced synaptic toxicity and cognitive dysfunction. Our results provide fundamental information on the molecular mechanisms of Aβ-induced synaptic malfunction and may offer new mechanism-based therapeutic targets to counteract downstream Aβ signaling.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26780512     DOI: 10.1038/nn.4225

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN: 1097-6256            Impact factor:   24.884


  52 in total

1.  Pten positively regulates brown adipose function, energy expenditure, and longevity.

Authors:  Ana Ortega-Molina; Alejo Efeyan; Elena Lopez-Guadamillas; Maribel Muñoz-Martin; Gonzalo Gómez-López; Marta Cañamero; Francisca Mulero; Joaquin Pastor; Sonia Martinez; Eduardo Romanos; M Mar Gonzalez-Barroso; Eduardo Rial; Angela M Valverde; James R Bischoff; Manuel Serrano
Journal:  Cell Metab       Date:  2012-03-07       Impact factor: 27.287

2.  PTEN is recruited to the postsynaptic terminal for NMDA receptor-dependent long-term depression.

Authors:  Sandra Jurado; Marion Benoist; Argentina Lario; Shira Knafo; Cortney N Petrok; José A Esteban
Journal:  EMBO J       Date:  2010-07-13       Impact factor: 11.598

3.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

4.  Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline.

Authors:  Konrad Talbot; Hoau-Yan Wang; Hala Kazi; Li-Ying Han; Kalindi P Bakshi; Andres Stucky; Robert L Fuino; Krista R Kawaguchi; Andrew J Samoyedny; Robert S Wilson; Zoe Arvanitakis; Julie A Schneider; Bryan A Wolf; David A Bennett; John Q Trojanowski; Steven E Arnold
Journal:  J Clin Invest       Date:  2012-04       Impact factor: 14.808

5.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

6.  Role of protein kinase B in Alzheimer's neurofibrillary pathology.

Authors:  Jin-Jing Pei; Sabiha Khatoon; Wen-Lin An; Maria Nordlinder; Toshihisa Tanaka; Heiko Braak; Ichiro Tsujio; Masatoshi Takeda; Irina Alafuzoff; Bengt Winblad; Richard F Cowburn; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Acta Neuropathol       Date:  2002-12-18       Impact factor: 17.088

7.  Alzheimer amyloid beta-peptide inhibits the late phase of long-term potentiation through calcineurin-dependent mechanisms in the hippocampal dentate gyrus.

Authors:  Qi-Sheng Chen; Wei-Zheng Wei; Takeshi Shimahara; Cui-Wei Xie
Journal:  Neurobiol Learn Mem       Date:  2002-05       Impact factor: 2.877

8.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes.

Authors:  L Holcomb; M N Gordon; E McGowan; X Yu; S Benkovic; P Jantzen; K Wright; I Saad; R Mueller; D Morgan; S Sanders; C Zehr; K O'Campo; J Hardy; C M Prada; C Eckman; S Younkin; K Hsiao; K Duff
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

9.  Reduced IGF-1 signaling delays age-associated proteotoxicity in mice.

Authors:  Ehud Cohen; Johan F Paulsson; Pablo Blinder; Tal Burstyn-Cohen; Deguo Du; Gabriela Estepa; Anthony Adame; Hang M Pham; Martin Holzenberger; Jeffery W Kelly; Eliezer Masliah; Andrew Dillin
Journal:  Cell       Date:  2009-12-11       Impact factor: 41.582

10.  NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration.

Authors:  Young-Don Kwak; Tao Ma; Shiyong Diao; Xue Zhang; Yaomin Chen; Janet Hsu; Stuart A Lipton; Eliezer Masliah; Huaxi Xu; Francesca-Fang Liao
Journal:  Mol Neurodegener       Date:  2010-11-10       Impact factor: 14.195

View more
  50 in total

1.  Pten regulates spindle pole movement through Dlg1-mediated recruitment of Eg5 to centrosomes.

Authors:  Janine H van Ree; Hyun-Ja Nam; Karthik B Jeganathan; Arun Kanakkanthara; Jan M van Deursen
Journal:  Nat Cell Biol       Date:  2016-05-30       Impact factor: 28.824

2.  Targeting PTEN interactions for Alzheimer's disease.

Authors:  Samuel Frere; Inna Slutsky
Journal:  Nat Neurosci       Date:  2016-03       Impact factor: 24.884

3.  Inhibition of PTEN Attenuates Endoplasmic Reticulum Stress and Apoptosis via Activation of PI3K/AKT Pathway in Alzheimer's Disease.

Authors:  Weigang Cui; Songtao Wang; Zhongping Wang; Zhiyong Wang; Chunli Sun; Yinghua Zhang
Journal:  Neurochem Res       Date:  2017-08-18       Impact factor: 3.996

4.  Up-regulation of miR-106a targets LIMK1 and contributes to cognitive impairment induced by isoflurane anesthesia in mice.

Authors:  Ning Zhang; Weiguang Ye; Tianlong Wang; Hui Wen; Lan Yao
Journal:  Genes Genomics       Date:  2020-01-13       Impact factor: 1.839

5.  Sulfhydration of AKT triggers Tau-phosphorylation by activating glycogen synthase kinase 3β in Alzheimer's disease.

Authors:  Tanusree Sen; Pampa Saha; Tong Jiang; Nilkantha Sen
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-12       Impact factor: 11.205

Review 6.  Mechanisms of action of amyloid-beta and its precursor protein in neuronal cell death.

Authors:  Yong Qi Leong; Khuen Yen Ng; Soi Moi Chye; Anna Pick Kiong Ling; Rhun Yian Koh
Journal:  Metab Brain Dis       Date:  2019-12-06       Impact factor: 3.584

7.  E46K α-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation.

Authors:  Ignacio Íñigo-Marco; Miguel Valencia; Laura Larrea; Ricardo Bugallo; Mikel Martínez-Goikoetxea; Iker Zuriguel; Montserrat Arrasate
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

8.  MEG biomarker of Alzheimer's disease: Absence of a prefrontal generator during auditory sensory gating.

Authors:  Sanja Josef Golubic; Cheryl J Aine; Julia M Stephen; John C Adair; Janice E Knoefel; Selma Supek
Journal:  Hum Brain Mapp       Date:  2017-07-17       Impact factor: 5.038

9.  Allopregnanolone Reverses Bioenergetic Deficits in Female Triple Transgenic Alzheimer's Mouse Model.

Authors:  Tian Wang; Jia Yao; Shuhua Chen; Zisu Mao; Roberta Diaz Brinton
Journal:  Neurotherapeutics       Date:  2020-01       Impact factor: 7.620

10.  GSK3α, not GSK3β, drives hippocampal NMDAR-dependent LTD via tau-mediated spine anchoring.

Authors:  Jonathan E Draffin; Carla Sánchez-Castillo; Alba Fernández-Rodrigo; Xavier Sánchez-Sáez; Jesús Ávila; Florence F Wagner; José A Esteban
Journal:  EMBO J       Date:  2020-11-16       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.